Page 38 - 磁共振成像2024年7期电子刊

磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7 特别关注｜｜Special Focus

存率和生活质量提供了重要的补充信息。 proliferation status of non-small cell lung cancer[J/OL]. Front Oncol,
2022, 12: 989131 [2023-07-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/
作者利益冲突声明：全体作者均声明无利益冲突。 PMC9562703/. DOI: 10.3389/fonc.2022.989131.
[17] ALÇıN G, ŞANLı Y, YEĞEN G, et al. The impact of primary tumor
作者贡献声明：王梅云设计本研究方案，对稿件 and locoregional metastatic lymph node SUV max on predicting survival
重要内容进行了修改，获得河南省医学科技攻关计 in patients with rectal cancer[J]. Mol Imaging Radionucl Ther, 2020,
29(2): 65-71. DOI: 10.4274/mirt.galenos.2020.40316.
划项目资助；周一航起草和撰写稿件，获取、分析并 [18] BRUCKMANN N M, KIRCHNER J, GRUENEISEN J, et al.
Correlation of the apparent diffusion coefficient (ADC) and standardized
解释本研究的数据；姜涵、孟楠、王鑫惠、刘雪、袁健 uptake values (SUV) with overall survival in patients with primary
non-small cell lung cancer (NSCLC) using F-FDG PET/MRI[J/OL]. Eur J
18
闵、杨阳、王哲获取、分析或解释本研究的数据，对稿 Radiol, 2021, 134: 109422 [2023-08-24]. https://pubmed.ncbi.nlm.nih.
件重要内容进行了修改；全体作者都同意发表最后 gov/33271432/. DOI: 10.1016/j.ejrad.2020.109422.
[19] PAESMANS M, GARCIA C, WONG C Y, et al. Primary tumour
的修改稿，同意对本研究的所有方面负责，确保本研 standardised uptake value is prognostic in nonsmall cell lung cancer: a
multivariate pooled analysis of individual data[J]. Eur Respir J, 2015,
究的准确性和诚信。 46(6): 1751-1761. DOI: 10.1183/13993003.00099-2015.
[20] KOK I C, HOOIVELD J S, VAN DE DONK P P, et al.
89
Zr-pembrolizumab imaging as a non-invasive approach to assess
参考文献[References] clinical response to PD-1 blockade in cancer[J]. Ann Oncol, 2022,
33(1): 80-88. DOI: 10.1016/j.annonc.2021.10.213.
[1] HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and [21] HSIEH C E, CHENG N M, CHOU W C, et al. Pretreatment primary
management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): tumor and nodal SUVmax values on 18F-FDG PET/CT images predict
446-454. DOI: 10.1038/nature25183. prognosis in patients with salivary gland carcinoma[J]. Clin Nucl Med,
[2] THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2018, 43(12): 869-879. DOI: 10.1097/RLU.0000000000002287.
2021, 398(10299): 535-554. DOI: 10.1016/S0140-6736(21)00312-3. [22] GARCÍA VICENTE A M, PÉREZ-BETETA J, AMO-SALAS M, et al.
[3] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA 18F-fluorocholine PET/CT in the prediction of molecular subtypes and
Cancer J Clin, 2016, 66(1): 7-30. DOI: 10.3322/caac.21332. prognosis for gliomas[J/OL]. Clin Nucl Med, 2019, 44(10): e548-e558
[4] DETTERBECK F C, BOFFA D J, KIM A W, et al. The eighth edition [2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/31306196/. DOI: 10.1097/
lung cancer stage classification[J]. Chest, 2017, 151(1): 193-203. DOI: RLU.0000000000002715.
10.1016/j.chest.2016.10.010. [23] QIN C X, YANG S R, SUN X, et al. 18F-FDG PET/CT for prognostic
[5] BOURREAU C, TREPS L, FAURE S, et al. Therapeutic strategies for stratification of patients with extranodal natural killer/T-cell lymphoma[J].
non-small cell lung cancer: experimental models and emerging Clin Nucl Med, 2019, 44(3): 201-208. DOI: 10.1097/RLU.0000000000
biomarkers to monitor drug efficacies[J/OL]. Pharmacol Ther, 2023, 002440.
242: 108347 [2023-09-01]. https://pubmed.ncbi.nlm.nih.gov/36642389/. [24] ONAL C, ERBAY G, GULER O C, et al. The prognostic value of
DOI: 10.1016/j.pharmthera.2023.108347. mean apparent diffusion coefficient measured with diffusion-weighted
[6] PARKER A L, BOWMAN E, ZINGONE A, et al. Extracellular matrix magnetic resonance image in patients with prostate cancer treated with
profiles determine risk and prognosis of the squamous cell carcinoma definitive radiotherapy[J/OL]. Radiother Oncol, 2022, 173: 285-291
subtype of non-small cell lung carcinoma[J/OL]. Genome Med, 2022, [2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/35753556/. DOI: 10.1016/
14(1): 126 [2023-09-01]. https://pubmed.ncbi.nlm.nih.gov/36404344/. j.radonc.2022.06.011.
DOI: 10.1186/s13073-022-01127-6. [25] SUROV A, PECH M, OMARI J, et al. Diffusion-weighted imaging
[7] JIA T, ZHANG Q G, XU H T, et al. The function of miR-637 in reflects tumor grading and microvascular invasion in hepatocellular
non-small cell lung cancer progression and prognosis[J]. Pulmonology, carcinoma[J]. Liver Cancer, 2021, 10(1): 10-24. DOI: 10.1159/000511384.
2023, 29(2): 111-118. DOI: 10.1016/j.pulmoe.2021.05.005. [26] KARAYAMA M, YOSHIZAWA N, SUGIYAMA M, et al. Intravoxel
18
[8] 郑庆中, 苏洁敏, 邓菁, 等 . F-FDG PET/CT 代谢参数对 116 例非小 incoherent motion magnetic resonance imaging for predicting the
细胞肺癌患者预后评估价值[J]. 中华肿瘤防治杂志, 2020, 27(16): long-term efficacy of immune checkpoint inhibitors in patients with
1309-1314. DOI: 10.16073/j.cnki.cjcpt.2020.16.06. non-small-cell lung cancer[J/OL]. Lung Cancer, 2020, 143: 47-54
ZHENG Q Z, SU J M, DENG J, et al. Prognostic value of F-FDG [2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/32203770/. DOI: 10.1016/
18
PET/CT metabolic parameters in patients with non-small cell lung j.lungcan.2020.03.013.
cancer[J]. Chin J Cancer Prev Treat, 2020, 27(16): 1309-1314. DOI: [27] WEISS E, FORD J C, OLSEN K M, et al. Apparent diffusion
10.16073/j.cnki.cjcpt.2020.16.06. coefficient (ADC) change on repeated diffusion-weighted magnetic
[9] LI X Y, WANG D W, YU L J. Prognostic and predictive values of resonance imaging during radiochemotherapy for non-small cell lung
18
metabolic parameters of F-FDG PET/CT in patients with non-small cancer: a pilot study[J/OL]. Lung Cancer, 2016, 96: 113-119 [2023-08-24].
cell lung cancer treated with chemotherapy[J/OL]. Mol Imaging, 2019, https://pubmed.ncbi.nlm.nih.gov/27133760/. DOI: 10.1016/j.lungcan.2016.
18: 1536012119846025 [2023-07-29]. https://pubmed.ncbi.nlm.nih.gov/ 04.001.
31144578/. DOI: 10.1177/1536012119846025. [28] SAMPATH S, RAHMANUDDIN S, SAHOO P, et al. Change in
[10] SHEN G H, LAN Y, ZHANG K, et al. Comparison of 18F-FDG PET/ apparent diffusion coefficient is associated with local failure after
CT and DWI for detection of mediastinal nodal metastasis in non-small stereotactic body radiation therapy for non-small cell lung cancer: a
cell lung cancer: a meta-analysis[J/OL]. PLoS One, 2017, 12(3): prospective clinical trial[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):
e0173104 [2023-08-11]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 659-663. DOI: 10.1016/j.ijrobp.2019.06.2536.
5333854/. DOI: 10.1371/journal.pone.0173104. [29] WINFIELD J M, WAKEFIELD J C, DOLLING D, et al.
[11] UMEDA Y, MORIKAWA M, ANZAI M, et al. Predictive value of Diffusion-weighted MRI in advanced epithelial ovarian cancer:
18
integrated F-FDG PET/MRI in the early response to nivolumab in apparent diffusion coefficient as a response marker[J]. Radiology,
patients with previously treated non-small cell lung cancer[J/OL]. J 2019, 293(2): 374-383. DOI: 10.1148/radiol.2019190545.
Immunother Cancer, 2020, 8(1): e000349 [2023-07-29]. https://www.ncbi. [30] PIANO F D, BUSCARINO V, MARESCA D, et al. Do DWI and
nlm.nih.gov/pmc/articles/PMC7213911/. DOI: 10.1136/jitc-2019-000349. quantitative DCE perfusion MR have a prognostic value in high-grade
[12] FUJII S, GONDA T, YUNAGA H. Clinical utility of serous ovarian cancer?[J]. Radiol Med, 2019, 124(12): 1315-1323.
diffusion-weighted imaging in gynecological imaging: revisited[J/OL]. DOI: 10.1007/s11547-019-01075-z.
Invest Radiol, 2024, 59(1): 78-91 [2023-08-22]. https://pubmed.ncbi. [31] SJÖHOLM T, KORENYUSHKIN A, GAMMELGÅRD G, et al.
nlm.nih.gov/37493356/. DOI: 10.1097/RLI.0000000000001004. Whole body FDG PET/MR for progression free and overall survival
18
[13] HUANG Z, LI X C, WANG Z X, et al. Application of simultaneous prediction in patients with relapsed/refractory large B-cell lymphomas
F-FDG PET with monoexponential, biexponential, and stretched undergoing CAR T-cell therapy[J/OL]. Cancer Imaging, 2022, 22(1):
exponential model-based diffusion-weighted MR imaging in assessing 76 [2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/36575477/. DOI:
the proliferation status of lung adenocarcinoma[J]. J Magn Reson 10.1186/s40644-022-00513-y.
Imaging, 2022, 56(1): 63-74. DOI: 10.1002/jmri.28010. [32] OHNO Y, KOYAMA H, YOSHIKAWA T, et al. Diffusion-weighted
[14] EVANGELISTA L, ZATTONI F, CASSARINO G, et al. PET/MRI in MRI versus 18F-FDG PET/CT: performance as predictors of tumor
prostate cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med treatment response and patient survival in patients with non-small cell
Mol Imaging, 2021, 48(3): 859-873. DOI: 10.1007/s00259-020-05025-0. lung cancer receiving chemoradiotherapy[J]. AJR Am J Roentgenol,
[15] HSU C Y, DOUBROVIN M, HUA C H, et al. Radiomics features 2012, 198(1): 75-82. DOI: 10.2214/AJR.11.6525.
differentiate between normal and tumoral high-fdg uptake[J/OL]. Sci [33] LIU J F, LV H X, DONG J L, et al. Diffusion-weighted magnetic
Rep, 2018, 8(1): 3913 [2023-08-22]. https://pubmed.ncbi.nlm.nih.gov/ resonance imaging for early detection of chemotherapy resistance in
29500442/. DOI: 10.1038/s41598-018-22319-4. non-small cell lung cancer[J/OL]. Med Sci Monit, 2019, 25: 6264-6270
[16] FENG P Y, SHAO Z H, DONG B, et al. Application of diffusion [2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/31476196/. DOI: 10.12659/
18
kurtosis imaging and F-FDG PET in evaluating the subtype, stage and MSM.914236.
https://www.chinesemri.com ·31 ·